Intranuclear nucleolin distribution during cell cycle progression in human invasive ductal breast carcinomas in relation to estrogen receptor status

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3957-3962

  Masiuk, Marek ^a   Urasinska, Elzbieta ^a   Domagala, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Cell cycle; Ductal breast cancer; Estrogen receptor; Nucleolin; Nucleolus

Indexed keywords

DNA; ESTROGEN RECEPTOR; NUCLEOLIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL POPULATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER SCANNING CYTOMETRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE; CELL NUCLEUS; FEMALE; HUMANS; PHOSPHOPROTEINS; RECEPTORS, ESTROGEN; RNA-BINDING PROTEINS;

EID: 37549007857     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Dundr M and Misteli T: Functional architecture in the cell nucleus. Biochem J 356: 297-310, 2001.
2. Scheer U and Benavente R: Functional and dynamic aspects of the mammalian nucleolus. BioEssays 12: 14-21, 1990.
3. Ginisty H, Sicard H, Roger B and Bouvet P: Structure and functions of nucleolin. J Cell Sci 112: 761-772, 1999.
4. Roussel P, Belenguer P, Amalric F and Hernandez-Verdun D: Nucleolin is an Ag-NOR protein; this property is determined by its amino-terminal domain independently of its phosphorylation state. Exp Cell Res 203: 259-269, 1992.
5. Ghisolfi-Nieto L, Joseph G, Puvion-Dutilleul F, Amalric F and Bouvet P: Nucleolin is a sequence-specific RNA-binding protein: characterization of targets on pre-ribosomal RNA. J Mol Biol 260: 34-53, 1996.
6. Lapeyre B, Amalric F, Ghaffari SH, Rao SV, Dumbar TS and Olson MO: Protein and cDNA sequence of a glycine-rich, dimethylarginine-containing region located near the carboxyl-terminal end of nucleolin (C23 and 100 kDa). J Biol Chem 261: 9167-9173, 1986.
7. Spector DL, Ochs RL and Busch H: Silver staining, immunofluorescence and immunoelectron microscopic localisation of nucleolar phosphoproteins B23 and C23. Chromosoma 90: 139-148, 1984.
8. Lischwe MA, Richards RL, Busch RK and Busch H: Localization of phosphoprotein C23 to nucleolar structures and to the nucleolus organizer regions. Exp Cell Res 136: 101-109, 1981.
9. Gorczyca W, Smolewski P, Grabarek J, Ardelt B, Ita M, Melamed M and Darzynkiewicz Z: Morphometry of nucleoli and expression of nucleolin analyzed by laser scanning cytometry in mitogenically stimulated lymphocytes. Cytometry 45: 206-213, 2001.
10. Ochs R, Lischwe M, O'Leary P and Busch H: Localisation of nucleolar phosphoproteins B23 and C23 during mitosis. Exp Cell Res 146: 139-149, 1983.
11. Masiuk M, Urasinska E and Domagala W: Simultaneous measurement of nucleolin and estrogen receptor in breast cancer cells by laser scanning cytometry. Anticancer Res 24: 963-966, 2004.
12. Hanakahi LA, Sun H and Maizels N: High affinity interactions of nucleolin with G-G-paired rDNA. J Biol Chem 274: 15908-15912, 1999.
13. Herrera AH and Olson MO: Association of protein C23 with rapidly labeled nucleolar RNA Biochemistry 25: 6258-6264, 1986.
14. Erard M, Lakhdar-Ghazal F and Amalric F: Repeat peptide motifs which contain beta-turns and modulate DNA condensation in chromatin. Eur J Biochem 191: 19-26, 1990.
15. Ginisty H, Amalric F and Bouvet P: Nucleolin functions in the first step of ribosomal RNA processing. EMBO J 17: 1476-1486, 1998.
16. Ginisty H, Serin G, Ghisolfi-Nieto L, Roger B, Libante V, Amalric F and Bouvet P: Interaction of nucleolin with an evolutionarily conserved pre-ribosomal RNA sequence is required for the assembly of the primary processing complex. J Biol Chem 275: 18845-18850, 2000.
17. Beekman JM, Allan GF, Tsai SY, Tsai MJ and O'Malley BW: Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7: 1266-1274, 1993.
18. Nilsson S and Gustafsson JA: Estrogen receptor transcription and transactivation. Basic aspects of estrogen action. Breast Cancer Res 2: 360-366, 2000.
19. Tafjord S, Bohler PJ, Risberg B and Torlakovic E: Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Diagn Cytopathol 26: 137-141, 2002.
20. Scawn R and Shousha S: Morphologic spectrum of estrogen receptor-negative breast carcinoma. Arch Pathol Lab Med 126: 325-330, 2002.
21. Jensen ML, Kiaer H and Meisen F: Medullary breast carcinoma vs. poorly differentiated ductal carcinoma: an immunohistochemical study with keratin 19 and oestrogen receptor staining. Histopathology 29: 241-245, 1996.
22. Domagala W, Markiewski M, Kubiak R, Bartkowiak J and Osborn M: Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 423: 497-502, 1993.
23. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A and Pouillart P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77: 113-120, 1996.
24. Bejar J, Sabo E, Eldar S, Lev M, Misselevich I and Boss JH: The prognostic significance of the semiquantitatively determined estrogen receptor content of breast carcinomas. Clinicopathological study. Pathol Res Pract 198: 455-460, 2002.
25. Bundred NJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137-142, 2001.
26. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA and Sutherland RL: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179-186, 2003.
27. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR and Sloane JP: Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer 84: 1064-1069, 2001.
28. Bankfalvi A, Ofner D, Schmid KW, Schmitz KJ, Breukelmann D, Krech R and Bocker W: Standarized in situ AgNOR analysis in breast pathology: diagnostic and cell kinetic implications. Pathol Res Pract 195: 219-229, 1999.
29. Ruschoff J, Neumann K, Contractor H, Plate K and Thomas C: Assessment of nucleolar organizer regions by automatic image analysis in breast cancer: correlation with DNA content, proliferation rate, receptor status and histopathology grading. J Cancer Res Clin Oncol 116: 480-485, 1990.
30. Gunther L, Hufnagl P, Winzer KJ and Guski H: Different proliferation patterns in breast cancer: AgNOR measurements in ER-negative and ER-positive tumor cells. Analyt Cell Pathol 20: 155-162, 2000.
31. Raymond WA and Leong AS-Y: Nucleolar organizer regions relate to growth fraction in human breast carcinoma. Human Pathol 20: 741-746, 1989.
32. Canet V, Montmasson MP, Urson Y, Giroud F and Brutal G: Correlation between silver-stained nucleolar organizer region area and cell cycle time. Cytometry 43: 110-116, 2001.
33. Kruger S, Stahlhut M and Muller H: Cell cycle-dependent AgNOR analysis in invasive breast cancer. Analyt and Quant Cytol and Histol 22: 358-363, 2000.
34. Sirri V, Roussel P, Gendron MC and Hernandez-Verdun D: Amount of the two major Ag-NOR proteins, nucleolin and protein B23 is cell-cycle dependent. Cytometry 28: 147-156, 1997.
35. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
36. 2 phases. J Cell Sci 108: 3427-3441, 1995.
37. Pession A, Farabegoli F, Trere D, Novello F, Montanaro L, Sperti S, Rambelli F and Derenzini M: The Ag-NOR proteins and transcription and duplication of ribosomal genes in mammalian nucleoli. Chromosomes 100: 242-250, 1991.
38. Giri DD, Nottingham JF, Lawry J, Dundas SAC and Underwood JCE: Silver-binding nucleolar organizer regions (AgNORs) in benign and malignant breast lesions: correlations with ploidy and growth phase by DNA flow cytometry. J Pathol 157: 307-313, 1989.
39. Nakayama K and Abe R: Argyrophilic nucleolar organizer region (AgNOR) area per nucleus as a prognostic factor in breast cancer. J Surg Oncol 60: 160-167, 1995.
40. Derenzini M, Sirri V, Trere D and Ochs RL: The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 73: 497-502, 1995.
41. Derenzini M and Trere D: Standarization of interphase Ag-NOR measurement by means of an automated image analysis system using lymphocytes as an internal control. J Pathol 165: 337-342, 1991.
42. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F and Adnet JJ: Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 18: 5-14, 1986.
43. Sacks NP, Robertson JF, Ellis IO, Nicholson RI, Crocker J and Blarney RW: Silver-stained nucleolar organiser region counts are of no prognostic value in primary breast cancer. Eur J Surg Oncol 18: 98-102, 1992.
44. Darzynkiewicz Z, Traganos F, Kapuscinski J, Staiano-Coico L and Melamed MR: Accessibility of DNA in situ to various fluorochromes: relationship to chromatin changes during erythroid differentiation of Friend leukemia cells. Cytometry 5: 355-363, 1984.
45. Kamentsky LA: Laser scanning cytometry. In: Cytometry. Darzynkiewicz Z, Crissmann HA and Robinson JP (eds.). Academic Press, pp. 51-87, 2001.